Pfizer’s Q3 Profit Tumbles on Lipitor Patent Expiration; Guidance Lowered; New $10 Billion Buyback Program Announced (PFE)

Comment

Shutterstock photo

Drug maker Pfizer Inc. ( PFE ) on Thursday posted in-line third quarter profits, although its revenue missed expectations, and unveiled plans for a massive new $10 billion share buyback program.

The New York-based company reported third quarter net income of $3.21 billion, or 43 cents per share, compared with $3.74 billion, or 48 cents per share, in the year-ago period. Excluding special items, adjusted profit was 53 cents per share.

Revenue plunged 16% from last year to $14 billion.

On average, Wall Street analysts expected a matching profit of 53 cents per share, albeit on higher revenue of $14.64 billion.

Looking ahead, PFE lowered its full-year 2012 earnings forecast. The company now expects 2012 earnings of $2.14 to $2.17 per share, down from $2.14 to $2.22 previously.

In another announcement, Pfizer's board of directors approved plans for a massive new $10 billion share buyback program. The new program is in addition its its current repurchase plan, which currently has about $4.1 billion remaining.

Pfizer shares fell 41 cents, or -1.7%, in premarket trading Thursday.

Pfizer Inc. ( PFE ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com



This article appears in: Investing , Stocks


More from Dividend.com







Dividend.com
Contributor:

Dividend.com

Dividends
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com